From football fields to military training grounds, head injuries are leaving lasting marks on the brain in ways we're only ...

Pegcetacoplan significantly reduces proteinuria in patients with recurrent C3 glomerulopathy, or primary immune-complex ...

Omeros Corporation OMER recently announced that the FDA approved its YARTEMLEA (narsoplimab-wuug) to treat hematopoietic stem ...

Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...

Seattle, USA-based biotech Omeros Corp saw its shares leap 75.5% to $15.36 by close of trading Wednesday, as it revealed that the US Food and Drug Administration (FDA) has approved its Yartemlea ...

The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea (narsoplimab-wuug) for hematopoietic stem cell transplant- associated thrombotic ...

Recent advances in the understanding of immune-mediated neurological disorders have led to a paradigm shift toward pathophysiology-directed therapies. Central to this progress is a deeper appreciation ...

In a highly anticipated article, FDA officials Vinay Prasad, M.D., and Martin Makary, M.D., outlined a novel regulatory pathway that could trigger a seismic shift in how bespoke gene editing therapies ...

Psychedelics—frequently recognized as substances such as LSD, psilocybin, and DMT—not only alter perception, mood, and cognition, but they often cause hallucinations. That said, they have also been ...

AMP-activated protein kinase (AMPK) plays a central role in maintaining energy balance in cells, especially under energy stress. While upstream activation by the kinase LKB1 is well recognized, the ...

ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...